丰原药业 2025 年第二次临时股东会 法律意见书 安徽径桥律师事务所 关于安徽丰原药业股份有限公司 2025 年第二次临时股东会法律意见书 遵照《中华人民共和国证券法》（以下简称《证券法》）、《中华人民共和国公司 法》（以下简称《公司法》）、《上市公司股东会规则》（以下简称《股东会规则》）、《关 于加强社会公众股股东权益保护的若干规定》（以下简称《若干规定》）等法律、法 规及《安徽丰原药业股份有限公司章程》（以下简称《公司章程》）的有关规定，安 徽径桥律师事务所（以下简称"本所"）接受安徽丰原药业股份有限公司（以下简称"公 司"）的专项委托，指派常合兵、洪锦律师出席公司 2025 年第二次临时股东会（以 下简称"本次股东会"），并就公司本次股东会的召集、召开程序、出席会议人员资格、 股东会的表决程序等相关问题出具法律意见。 本所仅依据法律意见书出具日前已经发生或存在的事实及本所律师对我国法律、 法规的理解发表法律意见。 为出具本法律意见书，本所律师审查了公司提供的与本次股东会有关的文件。 经本所律师核对，这些文件中的副本或复印件，均与原件相符。公司向本所保证并 承诺，其向本所提供的所有文件资料（包括原始书面 ...

股票简称：丰原药业 股票代码：000153 公告编号：2025-039 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 安徽丰原药业股份有限公司（以下简称"公司"）股东马鞍山丰原企业管理有限 公司于近日将持有公司的 924 万股（占公司总股本的 1.99%）无限售流通股（以下简 称"标的股份"）在国元证券股份有限公司办理了约定购回式证券交易。具体事项如 下： 安徽丰原药业股份有限公司 关于股东进行约定购回式证券交易 暨持股比例变动超过 1%的公告 股东马鞍山丰原企业管理有限公司保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、约定购回式证券交易情况 | 马鞍山丰原企业管理 | 国元证券股份 | 924 | 2026 年 月 | 10 | 28 | | --- | --- | --- | --- | --- | --- | | 参与交易的公司股东 有限公司 | 参与交易的证券公司 有限公司 | 证券交易数量（万股） | 购回期限 到期购回 | | 日 | 二、本次交易前后持股情况 | 股东名称 | 股份性质 | 交易前 | | 交易后 | | | --- | - ...

股票简称：丰原药业 股票代码：000153 公告编号：2025-038 安徽丰原药业股份有限公司 关于 2022 年限制性股票激励计划第三个解除限售期 解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述或 者重大遗漏。 特别提示： 1、2022 年限制性股票激励计划第三个限售期解除限售数量为 8,242,500 股，占 目前公司总股本比例为 1.7734%。 2、本次解除限售的限制性股票可上市流通日为 2025 年 11 月 3 日。 安徽丰原药业股份有限公司（以下简称"公司"）于 2025 年 10 月 22 日召开第十 届董事会三次会议和第十届监事会第三次会议，审议通过了《关于公司 2022 年限制 性股票激励计划第三个解除限售期解除限售条件成就的议案》，同意为符合解除限 售条件的 217 名激励对象的第三个解除限售期 8,242,500 股限制性股票办理解除限售 手续。根据《上市公司股权激励管理办法》及《公司 2022 年限制性股票激励计划（草 案）》的相关规定，公司已办理了上述限制性股票的解除限售及上市流通事宜，现 将具体情况公告如下： 一 ...

Group 1 - The company announced a guarantee for a loan of up to 10 million RMB for its wholly-owned subsidiary, Anhui Fengyuan Pharmaceutical Import and Export Co., Ltd., for a period of three years [3][7] - The board of directors approved the guarantee with a unanimous vote of 6 in favor, with no opposition or abstentions [3] - The total amount of external guarantees, including those for subsidiaries, will reach 440 million RMB, which accounts for 21.79% of the company's audited net assets for the year 2024 [9] Group 2 - The company will hold its second extraordinary general meeting of shareholders in 2025 on November 11, 2025, at 14:30 [15] - The meeting will combine on-site voting and online voting, with specific time slots for each [16] - Shareholders must register for the meeting between November 6, 2025, and November 11, 2025, and can do so through various methods [21][22]

Core Viewpoint - Fengyuan Pharmaceutical (000153.SZ) reported a decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved an operating revenue of 3.125 billion yuan, representing a year-on-year decrease of 4.18% [1] - The net profit attributable to shareholders of the listed company was 100 million yuan, down 31.92% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 74.9151 million yuan, reflecting a year-on-year decline of 36.39% [1]

Core Viewpoint - Fengyuan Pharmaceutical (000153.SZ) reported a decline in both revenue and net profit for the first three quarters of the year, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for the first three quarters was 3.125 billion yuan, a year-on-year decrease of 4.18% [1] - The net profit attributable to shareholders was 100 million yuan, reflecting a year-on-year decline of 31.92% [1] - The net profit excluding non-recurring gains and losses was 74.915 million yuan, down 36.39% year-on-year [1]

Group 1 - The company announced on October 23 that it will provide a guarantee for a loan of up to 10 million yuan for its wholly-owned subsidiary, Anhui Fengyuan Pharmaceutical Import and Export Co., Ltd. [1] - The board of directors approved the guarantee with a unanimous vote of 6 in favor, with no opposition or abstentions [1] - The total amount of external guarantees provided by the company will reach 440 million yuan, which accounts for 21.79% of the company's audited net assets for the year 2024 [1] Group 2 - As of the report date, the market capitalization of Fengyuan Pharmaceutical is 3.2 billion yuan [2] - The revenue composition for the first half of 2025 shows that retail distribution of pharmaceuticals accounts for 63.78%, manufacturing of pharmaceuticals accounts for 34.4%, and other businesses account for 1.82% [1]

Core Viewpoint - The company has adjusted the repurchase price of the restricted stock incentive plan from 2.77 CNY/share to 2.67 CNY/share due to the implementation of the 2024 profit distribution plan, which includes a cash dividend of 1 CNY for every 10 shares [1][3][4]. Group 1: Background of the Incentive Plan - The restricted stock incentive plan was approved in August 2022, granting 19.97 million shares to 223 participants at a price of 4.13 CNY/share [2]. - The plan has undergone multiple approvals and implementations, with the board reviewing related matters periodically [2]. Group 2: Details of the Price Adjustment - The adjustment is based on the formula that accounts for cash dividends affecting stock prices, specifically reducing the repurchase price by the dividend amount of 0.1 CNY/share [3]. - The new repurchase price is calculated as follows: 2.77 CNY - 0.1 CNY = 2.67 CNY/share [3]. Group 3: Impact on the Company and Compliance - The company stated that the price adjustment will not materially affect its financial status or operational results [4]. - The adjustment has followed necessary internal approval processes, with legal opinions confirming compliance with relevant laws and regulations [4]. Group 4: Future Considerations - Following the price adjustment, the company will handle any future repurchase and cancellation of restricted stocks at the new price [5]. - Market analysts suggest that this adjustment is a standard practice to maintain the fairness and effectiveness of the incentive plan, potentially enhancing the motivation of the core team [5].

Core Insights - Fengyuan Pharmaceutical reported a revenue of 3.125 billion yuan for the first three quarters of 2025, representing a year-on-year decline of 4.18% [1] - The net profit attributable to shareholders of the listed company was 100 million yuan, down 31.92% year-on-year [1] - Basic earnings per share decreased to 0.2158 yuan, reflecting a decline of 31.90% compared to the previous year [1]

现就有关事项说明如下： 股票简称：丰原药业 股票代码：000153 公告编号：2025-034 安徽丰原药业股份有限公司 关于回购注销部分限制性股票的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述或 者重大遗漏。 安徽丰原药业股份有限公司（下称"公司"）第十届董事会第三次会议于 2025 年 10 月 22 日在公司办公楼第一会议室召开。本次会议审议通过了《关于回购注销部分 限制性股票的议案》，同意回购注销 1 名因个人原因离职已不符合激励资格和 2 名因 个人年度考核结果为"不合格"而未满足解除限售条件的 3 名激励对象已获授但尚未 解除限售的限制性股票 88,200 股。 一、2022 年限制性股票激励计划简述及已履行的相关审批程序 1、2022 年 8 月 12 日，公司召开第九届董事会第二次（临时）会议，审议通过 《关于<公司 2022 年限制性股票激励计划（草案）>及摘要的议案》、《关于<公司 2022 年限制性股票激励计划实施考核管理办法>的议案》、《关于提请股东大会授权董事会 办理公司 2022 年限制性股票激励计划有关事项的议案》。公司独立董事就本次激励 ...